OBJECT: The authors previously have demonstrated that acute treatment with pravastatin after aneurysmal subarachnoid hemorrhage (SAH) can ameliorate vasospasm-related delayed ischemic neurological deficits (DINDs). In the current study, they test the hypothesis that these effects are associated with improvement in indices describing autoregulation of cerebral blood flow. METHODS: In this double-blind study, 80 patients between the ages of 18 and 84 years who had aneurysmal SAH were randomized equally to receive either 40 mg of oral pravastatin or placebo once daily for up to 14 days (medication was started 1.8 x 1.3 days after ictus). Autoregulation was measured using a daily transient hyperemic response test (THRT) on transcranial Doppler ultrasonography (800 measurements in 80 patients), and data were compared between the pravastatin and placebo groups and between patients with or without vasospasm, DINDs, or unfavorable outcome. Measurement of autoregulation also was performed using the pressure-reactivity index, a moving correlation coefficient between mean arterial and intracranial pressures (Days 0-5, 132 measurements in 32 patients). There was no difference in baseline autoregulation indices between the trial groups. The members of the pravastatin group not only had a shorter duration of impaired autoregulation but also had stronger transient hyperemic response ratios (THRRs) bilaterally. A negative correlation existed between the mean flow velocity in the middle cerebral artery and THRRs. Onset of DINDs occurred when bilateral autoregulation failed. On Days 3, 4, and 5, the pressure-reactivity index correlated significantly with ipsilateral impaired autoregulation. CONCLUSIONS: The neuroprotective effects of acute treatment with pravastatin following aneurysmal SAH are associated with enhancement of autoregulation. A routine and daily assessment of cerebral autoregulation by using the THRT may help identify patients at high risk of DINDs.
OBJECT: The authors previously have demonstrated that acute treatment with pravastatin after aneurysmal subarachnoid hemorrhage (SAH) can ameliorate vasospasm-related delayed ischemic neurological deficits (DINDs). In the current study, they test the hypothesis that these effects are associated with improvement in indices describing autoregulation of cerebral blood flow. METHODS: In this double-blind study, 80 patients between the ages of 18 and 84 years who had aneurysmal SAH were randomized equally to receive either 40 mg of oral pravastatin or placebo once daily for up to 14 days (medication was started 1.8 x 1.3 days after ictus). Autoregulation was measured using a daily transient hyperemic response test (THRT) on transcranial Doppler ultrasonography (800 measurements in 80 patients), and data were compared between the pravastatin and placebo groups and between patients with or without vasospasm, DINDs, or unfavorable outcome. Measurement of autoregulation also was performed using the pressure-reactivity index, a moving correlation coefficient between mean arterial and intracranial pressures (Days 0-5, 132 measurements in 32 patients). There was no difference in baseline autoregulation indices between the trial groups. The members of the pravastatin group not only had a shorter duration of impaired autoregulation but also had stronger transient hyperemic response ratios (THRRs) bilaterally. A negative correlation existed between the mean flow velocity in the middle cerebral artery and THRRs. Onset of DINDs occurred when bilateral autoregulation failed. On Days 3, 4, and 5, the pressure-reactivity index correlated significantly with ipsilateral impaired autoregulation. CONCLUSIONS: The neuroprotective effects of acute treatment with pravastatin following aneurysmal SAH are associated with enhancement of autoregulation. A routine and daily assessment of cerebral autoregulation by using the THRT may help identify patients at high risk of DINDs.
Authors: Michael N Diringer; Rajat Dhar; Michael Scalfani; Allyson R Zazulia; Michael Chicoine; William J Powers; Colin P Derdeyn Journal: Neurocrit Care Date: 2016-08 Impact factor: 3.210
Authors: Xiuyun Liu; Kais Gadhoumi; Ran Xiao; Nate Tran; Peter Smielewski; Marek Czosnyka; Steven W Hetts; Nerissa Ko; Xiao Hu Journal: Physiol Meas Date: 2019-01-23 Impact factor: 2.833
Authors: Karol P Budohoski; Marek Czosnyka; Peter J Kirkpatrick; Peter Smielewski; Luzius A Steiner; John D Pickard Journal: Nat Rev Neurol Date: 2013-02-19 Impact factor: 42.937
Authors: Andrew Silverman; Sreeja Kodali; Sumita Strander; Emily J Gilmore; Alexandra Kimmel; Anson Wang; Branden Cord; Guido Falcone; Ryan Hebert; Charles Matouk; Kevin N Sheth; Nils H Petersen Journal: Stroke Date: 2019-09-09 Impact factor: 7.914
Authors: Karol P Budohoski; Marek Czosnyka; Peter Smielewski; Georgios V Varsos; Magdalena Kasprowicz; Ken M Brady; John D Pickard; Peter J Kirkpatrick Journal: J Cereb Blood Flow Metab Date: 2012-12-12 Impact factor: 6.200